- Home
- BTQ vs CSTL Comparison
BTQ vs CSTL Comparison
Compare BTQ & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTQ
- CSTL
- Stock Information
- Founded
- BTQ 1983
- CSTL 2007
- Country
- BTQ Canada
- CSTL United States
- Employees
- BTQ N/A
- CSTL N/A
- Industry
- BTQ
- CSTL Medical Specialities
- Sector
- BTQ
- CSTL Health Care
- Exchange
- BTQ Nasdaq
- CSTL Nasdaq
- Market Cap
- BTQ 728.0M
- CSTL 697.9M
- IPO Year
- BTQ N/A
- CSTL 2019
- Fundamental
- Price
- BTQ $6.94
- CSTL $22.72
- Analyst Decision
- BTQ
- CSTL Strong Buy
- Analyst Count
- BTQ 0
- CSTL 6
- Target Price
- BTQ N/A
- CSTL $37.67
- AVG Volume (30 Days)
- BTQ 2.7M
- CSTL 350.0K
- Earning Date
- BTQ 11-14-2025
- CSTL 11-03-2025
- Dividend Yield
- BTQ N/A
- CSTL N/A
- EPS Growth
- BTQ N/A
- CSTL N/A
- EPS
- BTQ N/A
- CSTL N/A
- Revenue
- BTQ $653,726.00
- CSTL $346,269,000.00
- Revenue This Year
- BTQ $100.70
- CSTL N/A
- Revenue Next Year
- BTQ $669.96
- CSTL N/A
- P/E Ratio
- BTQ N/A
- CSTL N/A
- Revenue Growth
- BTQ 884.39
- CSTL 20.40
- 52 Week Low
- BTQ $0.18
- CSTL $14.59
- 52 Week High
- BTQ $8.37
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- BTQ N/A
- CSTL 52.33
- Support Level
- BTQ N/A
- CSTL $22.05
- Resistance Level
- BTQ N/A
- CSTL $23.19
- Average True Range (ATR)
- BTQ 0.00
- CSTL 1.04
- MACD
- BTQ 0.00
- CSTL -0.19
- Stochastic Oscillator
- BTQ 0.00
- CSTL 38.34
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.